Last mentioned: Mar 24, 2026
DOJ Missouri Filing
DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
Legislative Action
Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Louisiana Precedent
DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.
Amended Complaint
AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.
Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.
Supreme Court Ruling
SCOTUS maintains access to mifepristone by dismissing a challenge to FDA's rules on procedural grounds.
Pharmacy Certification
FDA updates REMS to allow retail pharmacies to dispense mifepristone upon certification.
Mail-Order Authorization
FDA permanently removes the requirement for in-person dispensing, allowing for telehealth and mail delivery.
Protocol Expansion
FDA extends usage window to 10 weeks and reduces required office visits from three to one.
Initial FDA Approval
FDA approves mifepristone for medical termination of pregnancy through seven weeks.
Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
House Republicans have introduced the Clean Water For All Life Act, a novel regulatory attempt to classify abortion pill remains as environmental pollutants. The bill seeks to mandate 'catch kits' for patients, ban mail-order medication, and impose severe criminal penalties on providers and users.
The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
This page surfaces every story mentioning mifepristone across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where mifepristone was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |